| | Presentation | Media | Date |
| AlzeCure Pharma presentation at Redeye Neurology Day October 15
| |
|
October 15, 2025
|
| CEO Martin Jönsson presents AlzeCure Pharma, the project pipeline and the science behind it.
|
|
|
September 26, 2025
|
| Poster from NeuPSIG 2025 - Analgesic and anti-inflammatory effects of ACD137, a potent and selective negative allosteric modulator of TrkA.
|
|
|
September 8, 2025
|
| Poster from NeuPSIG 2025 - The TRPV1 antagonist ACD440 Gel as a tool in pain precision medicine, results of a post hoc analysis
|
| |
September 4, 2025
|
| Presentation about the Orphan Drug Market and its opportunities and development by Dimitrina Dimitrova, Karolinska
|
|
|
August 27, 2025
|
| Presentation about Painless ACD440 and its orphan designation and opportunity within erytheromelalgia by AlzeCure’s CMO Märta Segerdahl
|
|
|
August 27, 2025
|
| Seminar on Painless ACD440 against erytheromelalgia and the opportunities within the orphan drug market and for erytheromelalgia. With presentations by AlzeCure’s CMO Märta Segerdahl, Dimitrina Dimitrova, consultant, and AlzeCure’sCEO Martin Jönsson
|
|
|
August 27, 2025
|
| AlzeCure Pharma's CEO, Martin Jönsson at BioStock - Progress & the Right issue. 8 July 2025 (Swedish)
| |
|
July 8, 2025
|
| AlzeCure Pharma's CEO, Martin Jönsson at BioStock – A good momentum, July 8, 2025 (Swedish)
| |
|
July 8, 2025
|
| AlzeCure Pharma's CEO, Martin Jönsson at Aktiespararna, July 8, 2025 (Swedish)
| |
|
July 8, 2025
|
| AlzeCure´s CEO, Martin Jönsson at BioStock, July 2, 2025
| |
|
July 2, 2025
|
| AlzeCure Pharma´s CEO, Martin Jönsson & CSO, Johan Sandin at Redeye (Swedish)
| |
|
June 23, 2025
|
| AlzeCure Pharma´s CEO, Martin Jönsson at Redeye (Swedish)
| |
|
June 13, 2025
|
| AlzeCure Pharma´s CEO, Martin Jönsson present at Redeye Investor Forum
|
|
|
June 11, 2025
|
| AlzeCure Pharma´s CEO, Martin Jönsson presents at Aktiedagarna (Swedish)
| |
|
June 10, 2025
|
| Nordic Asia Life-science Summit
|
| |
May 28, 2025
|
| AlzeCure´s CEO, Martin Jönsson at Redeye Theme: Alzheimer & Parkinsons
|
|
|
April 8, 2025
|
| CEO, Martin Jönsson and CSO, Johan Sandin at Redeye - Indicates opportunities in obesity for NeuroRestore ACD856, (Swedish)
| |
|
April 7, 2025
|
| Further investigation on the immunomodulatory and anti-inflammatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer’s disease
|
| |
April 7, 2025
|
| Christina Parrado-Fernández summarizes the abstract with preclinical data on NeuroRestore ACD856 demonstrating its anti-inflammatory and immunomodulatory effects, presented at the international conference AD/PD 2025, in Vienna on April 1-5.
|
|
|
April 1, 2025
|
| CEO Martin Jönsson at Finwire - Report for the fourth quarter (Swedish)
| |
|
February 27, 2025
|
| CEO Martin Jönsson at Finwire – The company's latest advances in Alzheimer's research (Swedish)
| |
|
February 27, 2025
|
| CEO, Martin Jönsson at Redeye - About Q4 reports etc. (Swedish)
| |
|
February 27, 2025
|
| CEO Martin Jönsson at Redeye - "Shows potentially revolutionary findings" (Swedish)
| |
|
February 25, 2025
|
| Summary of article that was publish in The Journal of Pharmacology and Experimental Therapeutics
|
|
|
February 24, 2025
|
| SITDOWN at Finwire - Receives EU grant from EIC
| |
|
February 21, 2025
|
| AlzeCure at Redeye – AlzeCure receives EU grant for Phase 2 clinical trial of NeuroRestore ACD856 for Alzheimer's disease (Swedish)
| |
|
February 18, 2025
|
| The Presentation on the NeuroRestore ACD856 publication: “Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease” by Pontus Forsell et al from 2024, published in Pharmaceuticals (2024; 17(8), 997
|
|
|
December 20, 2024
|
| CEO, Martin Jönsson at Redeye Theme Event Neurology
| |
|
December 3, 2024
|
| AlzeCure's CEO Martin Jönsson presented at Aktiespararnas Stora Aktiedagarna in Stockholm (Swedish)
| |
|
November 27, 2024
|
| CEO Martin Jönsson at Finwire - About the progress and in the future in Alzheimer's and pain. (Swedish)
| |
|
November 11, 2024
|
| Poster from Ctad 2024 - Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer’s disease
|
| |
October 29, 2024
|
| ACD440 – A novel non-opioid analgesic, with Märta Segerdahl, CMO and project manager - AlzeCure´s live event.
| |
|
October 23, 2024
|
| ACD440 – A novel non-opioid analgesic, with Dr. Rolf Karlsten - AlzeCure´s live event.
| |
|
October 23, 2024
|
| ACD440 – A novel non-opioid analgesic – From AlzeCures live-event.
| |
|
October 23, 2024
|
| CEO, Martin Jönsson to presented at Redeye’s Neurology Day, Presentation about AlzeCure, our Alzheimer and pain platforms, projects, etc.
| |
|
October 23, 2024
|
| Presentation about AlzeCure by CEO Martin Jönsson, presented at LSX Nordic Congress
| |
|
October 8, 2024
|
| Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the ACD856 poster on an anti-inflammatory effect to be presented at CTAD, October 1, 2024 (Swedish)
| |
|
October 1, 2024
|
| AlzeCures CEO, Martin Jönsson at Finwire (Swedish )
| |
|
August 27, 2024
|
| Watch the latest interview at Redeye with our CEO, Martin Jönsson (Swedish)
| |
|
August 20, 2024
|
| Alzecure’s pain project TrkA-NAM presented at the pain conference IASP, Augusti 5-9 2024 – Pharmalogical Effects of ACD137, a Potent and Selective Negative Allosteric Modulator of TrkA
|
| |
August 7, 2024
|
| CEO Martin Jönsson presents at Redeye Investor forum (Swedish)
| |
|
May 16, 2024
|
| Interview at Redeye with CEO, Martin Jönsson (Swedish)
| |
|
May 6, 2024
|
| Rights issue presentation with CEO Martin Jönsson (Swedish)
| |
|
May 2, 2024
|
| Interview at Finwire with Johan Sandin, CSO (Swedish)
| |
|
May 2, 2024
|
| SITDOWN at Finwire - AlzeCures CEO, Martin Jönsson about the rights issue (Swedish)
| |
|
May 2, 2024
|
| AlzeCure's CEO Martin Jönsson at Redeye (Swedish)
| |
|
April 11, 2024
|
| CEO Martin Jönsson presenting at Finwire (Swedish)
| |
|
April 10, 2024
|
| AlzeCure's CEO Martin Jönsson at Redeye's event on Alzheimer's (Swedish)
| |
|
March 21, 2024
|
| AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer’s conference, AD/PD 2024
|
|
|
March 7, 2024
|
| Welcome address, agenda & company overview, – Martin Jönsson, CEO, AlzeCure; AlzeCure Pharma expert event - Alzheimer’s around highly current gamma-secretase modulators
|
|
|
February 19, 2024
|
| Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – AlzeCure Pharma expert event with Johan Sandin, PhD, CSO, AlzeCure
|
|
|
February 19, 2024
|
| Alzheimer’s disease and the amyloid hypothesis – Professor Henrik Zetterberg, MD, PhD, Gothenburg University & University College London, AlzeCure Pharma expert event
|
|
|
February 19, 2024
|
| Expert Event - Advances in the treatment of Alzheimer’s disease – Small molecule Gamma-Secretase Modulators (GSMs) as promising disease-modifying treatments together
|
|
|
February 19, 2024
|
| AlzeCure at Nordic American Healthcare Conference, December 6-7, 2023
|
| |
December 6, 2023
|
| AlzeCure at Redeye Life Science Day 2023 on November 23, 2023
| |
|
November 23, 2023
|
| NeuroRestore ACD856, a Trk-PAM in clinical development for Alzheimer’s disease shows neuroprotective and neurorestorative effects_CTAD 2023
|
| |
October 25, 2023
|
| Clinical results from phase II study with ACD440 in patients with peripheral neuropathic pain. Scientific presentation at the Svenskt Smärtforum conference Oct 12- 13, 2023.
|
| |
October 12, 2023
|
| AlzeCure at Redeye Neurology Theme Event CEO Martin Jönsson presented and answered questions about the latest developments and the company’s plans going forward.
|
|
|
October 11, 2023
|
| Article from Life Science Sweden – DUAL ACTION AGAINST ALZHEIMER’S IN ALZSTATIN
|
| |
October 2, 2023
|
| AlzeCure ACD440 TRPV1 antagonist Ph 2 data, EFIC 2023
|
| |
September 20, 2023
|
| AlzeCure Pharma present at Finwire – CSO Johan Sandin
| |
|
September 5, 2023
|
| AlzeCure Pharma present at Finwire – CMO Märta Segerdahl
| |
|
September 5, 2023
|
| AlzeCure Pharma present at Finwire
| |
|
September 5, 2023
|
| AlzeCure presents at Redeye Growth Day on June 1st , 2023
| |
|
June 1, 2023
|
| AlzeCure Pharma’s CEO Martin Jönsson – Infocus interview at Redeye Growth Day on June 1th , 2023
| |
|
June 1, 2023
|
| AlzeCure Pharma – Capital Market Day May 17th, 2023
|
|
|
May 17, 2023
|
| NeuroRestore: Background & data supporting disease modifying effects with Pontus Forsell
|
|
|
May 17, 2023
|
| Alzheimer’s disease; Challenges & Opportunities with Professor Bengt Winblad Karolinska Institutet
|
|
|
May 17, 2023
|
| Presentation of the development of AlzeCure’s Alzheimer project Alzstatin and NeuroRestore
| |
|
May 17, 2023
|
| Alzstatin – A preventive treatment against Alzheimer’s – Background & Evolution with Johan Sandin
|
|
|
May 17, 2023
|
| Interview at Finwire with CEO Martin Jönsson
| |
|
May 9, 2023
|
| CEO Martin Jönsson at Redeye (Swedish)
| |
|
April 12, 2023
|
| In vitro and in vivo profile of AC-0027875 (Alzstatin ACD680), a novel gamma-secretase modulator for the prevention and treatment of Alzheimer’s disease; AD/PD 2023, March 28 – April 1, 2023
|
|
|
March 28, 2023
|
| Effects on neuroprotection and neuro plasticity by the clinical compound ACD856, a novel positive modulator of Trk-receptors from the NeuroRestore® platform; AD/PD 2023, March 28 – April 1, 2023
|
|
|
March 28, 2023
|
| Sitdown at Finwire with CEO Martin Jönsson
| |
|
March 1, 2023
|
| CEO Martin Jönsson’s interview with Redeye, the outcome of the issue and milestones in 2023, 9 January (Swedish)
| |
|
January 9, 2023
|
| Erik Penser – Interview with CSO Johan Sandin about AlzeCure’s projects.
| |
|
December 13, 2022
|
| Interview at Finwire news with CEO Martin Jönsson (The presentation will be held in Swedish).
| |
|
December 12, 2022
|
| Rights Issue presentation with CEO Martin Jönsson at Erik Penser Bank.
|
|
|
December 6, 2022
|
| Erik Penser – Interview with Martin Jönsson about the ongoing Rights Issue.
| |
|
December 6, 2022
|
| AlzeCure’s CEO Martin Jönsson presents at BioStock in connection with a new share issue, December 5, 2022.
| |
|
December 5, 2022
|
| CEO Martin Jönsson presents AlzeCure at BioStock.
| |
|
December 5, 2022
|
| Preclinical characterization of ACD856. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
| |
November 30, 2022
|
| AC-0027875, a novel gamma-secretase modulator. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
| |
November 30, 2022
|
| Quantitative EEG results from a multiple ascending dose study. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
| |
November 30, 2022
|
| CEO Martin Jönsson interviewed at Redeye Life Sciences Day on the company’s positive development & plans, as well as about the proposed rights issue in December and the positive progress in the Alzheimer’s market, and what this means for AlzeCure.
| |
|
November 24, 2022
|
| Martin Jönsson presented at Life Science Investor Conference the company’s successes and ongoing projects, as well as the company’s new share issue.
| |
|
November 23, 2022
|
| CEO Martin Jönsson presents AlzeCure’s progress and ongoing projects, as well as the company’s proposed share issue. (English)
| |
|
November 17, 2022
|
| Aktiespararna’s event with AlzeCure on November 16, 2022 – Martin Jönsson, AlzeCure’s CEO, presented the company’s progress and ongoing projects, as well as the company’s planned share issue. The presentation was held in Swedish.
| |
|
November 16, 2022
|
| CEO Martin Jönsson presented the company’s latest developments at Redeye Theme: Neurology on October 12, 2022.
| |
|
October 12, 2022
|
| CEO Martin Jönsson presented an update on our Pain management projects at Redeye Theme: Neurology on October 12.
| |
|
October 12, 2022
|
| The Trk-PAM ACD856 improves mitochondrial function and increases BDNF levels in primary cortical neurons; Scientific presentation at the ISMND Conference, Athens, October 10-12, 2022.
|
| |
October 11, 2022
|
| Analgesic and Anti-inflammatory Effects of Small Molecule Negative Allosteric Modulators of TrkA; Scientific presentation at the IASP Conference, Toronto, September 19-23, 2022.
|
| |
September 22, 2022
|
| Martin talks about the latest developments for AlzeCure including the phase 2 study with ACD 440 against neuropathic pain, the new positive clinical results with NeuroRestore ACD 856, our new patent and the new results with the pain project TrkA-NAM. (Swedish).
| |
|
September 12, 2022
|
| Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the latest clinical progress (Swedish).
| |
|
September 1, 2022
|
| Results From a Multiple Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors AAIC July – Aug 2022.
|
|
|
July 31, 2022
|
| Watch the interview with Aktiespararna at Finwire with AlzeCure’s CEO Martin Jönsson. (Swedish).
| |
|
July 1, 2022
|
| AlzeCure – Interview at Redeye with CEO Martin Jönsson about the phase II study with ACD440. (Swedish).
| |
|
June 23, 2022
|
| AlzeCure at Redeye Growth Day.
| |
|
June 2, 2022
|
| CEO Martin Jönsson Presenting at Redeye Growth Day.
| |
|
May 23, 2022
|
| The use of PathHunter cell lines to discover modulators of Trk-receptors. From HTS to phase 1; Scientific presentation at the ELRIG Conference, Gothenburg, May 10-12, 2022.
|
| |
May 10, 2022
|
| AlzeCure – Alzheimer event at Redeye (Swedish).
| |
|
May 3, 2022
|
| Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm.
|
| |
April 21, 2022
|
| Preliminary Results From a Single Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm,
|
| |
April 21, 2022
|
| Identification of a positive modulator of neurotrophin recptors with memory-enhancing effects and improved mitochondrial function; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research.
|
| |
April 21, 2022
|
| A positive modulator of neurotrophin receptors improves cognition and mitochondrial function; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022.
| |
|
March 17, 2022
|
| NeuroRestore – Preliminary results from a Single Ascending Dose study in healthy volunteers of ACD856, a positive modulator of Neurotrophin Trk-receptors; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022
|
|
|
March 15, 2022
|
| CSO Johan Sandin explains the science behind AlzeCure’s project portfolio and what distinguishes it from other pharma companies (Swedish).
| |
|
March 14, 2022
|
| CEO Martin Jönsson is interview by BioStock on the company’s latest developments, including the ongoing rights issue.
| |
|
March 14, 2022
|
| Watch the Analysisguide’s interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the future (in Swedish).
| |
|
March 14, 2022
|
| See CEO Martin Jönsson and CSO Johan Sandin, present upcoming events in the company and the ongoing issue (Swedish).
| |
|
March 11, 2022
|
| Watch the interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the ongoing issue (Swedish).
| |
|
March 9, 2022
|
| AlzeCure – New presentation at Penser (Swedish).
| |
|
February 24, 2022
|
| CEO Martin Jönsson presents at Aktiespararna (Swedish).
| |
|
January 31, 2022
|
| Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease (Text only).
|
| |
January 27, 2022
|
| Alzstatin – Development of novel ?-secretase modulators for the treatment of Alzheimer’s disease.
|
| |
January 27, 2022
|
| Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease, Scientific presentation at 11th Pharmaceutical Profiling meeting, January 27, 2022.
|
| |
January 27, 2022
|
| AlzeCure Pharma – Kapitalmarknadsdag.
| |
|
January 18, 2022
|
| AlzeCure medverkar på Erik Penser Banks temadag Life Science december 2, 2021 (Swedish)
|
|
|
December 2, 2021
|
| Follow us – Stay updated
| |
|
November 22, 2021
|
| AlzeCure Pharma – Redeye Life Science Day
| |
|
November 11, 2021
|
| AlzeCure update on the latest developments – Interview with CEO Martin Jönsson about the company, its projects developments in Alzheimer’s and pain, and future plans.
| |
|
October 22, 2021
|
| Alzecure presents at Healthcare Innovation Summit
|
|
|
October 7, 2021
|
| Characterization of positive allosteric modulators of TrkB for the treatment of depression
|
| |
October 2, 2021
|
| Alzecure Pharma – Naventus Life Science Summit
|
|
|
September 29, 2021
|
| Aktiespararna interview CEO Martin Jönsson – latest quarterly report and future prospects. (Swedish)
| |
|
September 20, 2021
|
| AlzeCure Pharma – Aktiedagen Stockholm. (Swedish)
| |
|
September 7, 2021
|
| Strategy Update on Alzheimer’s Disease & NeuroRestore
|
|
|
September 1, 2021
|
| Alzheimer’s disease and the neurotrophins BDNF/NGF by Prof. Maria Eriksdotter M.D., PhD
|
|
|
September 1, 2021
|
| Company Overview & Vision by Martin Jönsson CEO
|
|
|
September 1, 2021
|
| NeuroRestore Background and evolution by Dr Pontus Forsell, PhD Head of Discovery & Research
|
|
|
September 1, 2021
|
| Development plan for NeuroRestore ACD856 by Dr Johan Sandin, PhD Chief Scientific Officer
|
|
|
September 1, 2021
|
| ACD856 – a novel positive allosteric modulator of Trk-receptors in clinical development for the treatment of Alzheimer’s disease; Scientific presentation at AAIC, July 26-30, 2021
|
|
|
July 29, 2021
|
| About Alzstatin and drugs for Alzheimer’s disease – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)
| |
|
June 11, 2021
|
| About suffering from Alzheimer’s disease, diagnostics, care today and future needs – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)
| |
|
June 11, 2021
|
| Negative Allosteric Modulators of TrkA for the Treatment of Pain – Scientific presentation at the IASP conference on pain, June 2021
|
|
|
June 11, 2021
|
| About AlzeCure’s origin and development – An embryo that can be something big – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)
| |
|
June 11, 2021
|
| ACD440 – A Novel TRPV1 Antagonist for the Topical Treatment in Neuropathic Pain – Scientific presentation at the IASP conference on pain, June 2021
|
|
|
June 9, 2021
|
| Alzecure: CEO Martin Jönsson present at Redeye Growth Day
| |
|
June 7, 2021
|
| CEO presentation at the annual meeting (Swedish)
|
| |
May 20, 2021
|
| CEO Martin Jönsson after the company’s annual meeting
|
| |
May 17, 2021
|
| TrkA- NAM – Project in osteoarthritis & other severe pain conditions by Head of Discovery & Research Pontus Forsell, May 11, 2021
|
| |
May 11, 2021
|
| ACD 440 – A novel VR1 antagonist for neuropathic pain by CSO Johan Sandin, May 11, 2021
|
| |
May 11, 2021
|
| Chronic Pain – a high unmet medical need by CMO Märta Segerdahl, May 11, 2021
|
|
|
May 11, 2021
|
| Company overview and goals by CEO Martin Jönsson, May 11, 2021
|
|
|
May 11, 2021
|
| Update on Progress in the Painless Platform, May 11, 2021
|
|
|
May 11, 2021
|
| Alzecure: Interview with CEO Martin Jönsson and CSO Johan Sandin (video)
| |
|
April 20, 2021
|
| Alzecure: Interview with CEOMartin Jönsson (video). (Swedish)
| |
|
March 1, 2021
|
| Interview with Martin Jönsson CEO in Aktiespararna’s analysis guide
| |
|
February 8, 2021
|
| CEO Martin Jönsson presentation, Aktiedagen Lund
| |
|
January 27, 2021
|
| Interview with Johan Sandin (CSO) in Aktiespararna’s analysis guide
| |
|
January 22, 2021
|
| Improving Quality of Life for People with Neurodegenerative Diseases – Stockholm Researchers and Health Tech Companies
|
| |
January 14, 2021
|
| Alzecure: CEO Martin Jönsson presents at Redeye Life Science Day 2020
| |
|
December 1, 2020
|
| Scientific presentation on Alzstatin presented at the CTAD conference
|
| |
November 4, 2020
|
| Scientific presentation on the NeuroRestore® candidate ACD856 presented at the CTAD conference
|
| |
November 4, 2020
|
| Scientific and market update with professor Henrik Zetterberg on Alzheimer’s disease, bio-markers, potential future treatments, including Alzstatin and AlzeCure
| |
|
September 30, 2020
|
| AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)
| |
|
September 8, 2020
|
| AlzeCure Science & Market update about Alzheimer’s diseas and NeuroRestore (Swedish)
| |
|
September 1, 2020
|
| Scientific presentation about ACD856, a positive modulator of neurotrophin signaling reverses scopolamine- or age-induced cognitive deficits
|
|
|
April 5, 2020
|
| Get to know AlzeCure’s CEO Martin Jönsson – Redeye interview (Swedish)
| |
|
March 19, 2020
|
| AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)
| |
|
March 16, 2020
|
| Gamma-secretase modulation results in multiple anti-amyloidogenic effects in vivo; Scientific presentation at the AAT-AD/PD conference, Italy, March 15-18, 2018
|
| |
March 15, 2018
|
| About Alzheimers disease
| |
|
February 27, 2018
|
| About the project NeuroRestore®, symptomatic treatment of cognitive disorders such as in Alzheimer’s disease
| |
|
February 27, 2018
|
| Welcome to AlzeCure … Introduction film about the company (Swedish) – 1 minute
| |
|
February 27, 2018
|
| About the Alzstatin® project Disease modifying treatment of Alzheimer’s disease
| |
|
February 27, 2018
|
